# Themis Medicare (NSE: THEMISMED) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/THEMISMED · Pivot · prices to 22 Oct 2026

Themis Medicare (NSE: THEMISMED) closed at ₹98.08 on 22 Oct 2026, up 3.13% on the day. With a market capitalisation of ₹903 Cr, it ranks 1509th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 7.5% in FY25. Over the past year the share price has fallen 22.8%. Its 52-week range is ₹64.95 (30 Mar 2026) to ₹140.60 (7 Sep 2026); the last close is 30.2% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹77 Cr (+6.7% year on year) and net profit ₹2 Cr, on a consolidated basis. Promoters held 67.11% of the company as of 30 Jun 2026; 43.39% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹98.08 |
| Market cap | ₹903 Cr |
| ROE | 7.5% (FY25) |
| ROCE | 12.5% (FY25) |
| Debt to equity | 0.26 |
| 52-week high | ₹140.60 (7 Sep 2026) |
| 52-week low | ₹64.95 (30 Mar 2026) |
| 1-year return | −22.8% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹77 Cr | +6.7% | ₹2 Cr | — | ₹0.96 |
| Q3 FY26 | ₹90 Cr | −3.9% | ₹5 Cr | +48.7% | ₹1.10 |
| Q2 FY26 | ₹78 Cr | −33.3% | −₹5 Cr | −154.3% | −₹0.39 |
| Q1 FY26 | ₹98 Cr | −20.7% | −₹14 Cr | −175.3% | −₹1.54 |
| Q4 FY25 | ₹72 Cr | −26.7% | −₹8 Cr | −352.4% | −₹1.05 |
| Q3 FY25 | ₹94 Cr | +13.7% | ₹3 Cr | +54.0% | ₹0.06 |
| Q2 FY25 | ₹117 Cr | +11.7% | ₹10 Cr | +39.0% | ₹1.55 |
| Q1 FY25 | ₹123 Cr | +27.3% | ₹19 Cr | +49.1% | ₹2.68 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹406 Cr | ₹24 Cr |
| FY24 | ₹382 Cr | ₹25 Cr |
| FY23 | ₹354 Cr | ₹43 Cr |
| FY22 | ₹395 Cr | ₹62 Cr |
| FY21 | ₹231 Cr | ₹26 Cr |
| FY20 | ₹202 Cr | ₹16 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 67.11%
- Foreign institutions: 0.01%
- Domestic institutions: 0.01%
- Non-institutions: 32.87%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Lincoln Pharmaceuticals](https://app.pivotnow.in/stock/LINCOLN) | ₹517.50 | ₹1,037 Cr | 11.8 | — |
| [Sigachi Industries](https://app.pivotnow.in/stock/SIGACHI) | ₹26.24 | ₹1,003 Cr | — | — |
| [Laxmi Dental](https://app.pivotnow.in/stock/LAXMIDENTL) | ₹177.55 | ₹976 Cr | 33.7 | — |
| [Shree Ganesh Re](https://app.pivotnow.in/stock/SGRL) | ₹658.25 | ₹845 Cr | 47.7 | — |
| [Anuh Pharma](https://app.pivotnow.in/stock/ANUHPHR) | ₹80.29 | ₹805 Cr | 19.6 | — |
| [Kilitch Drugs (India)](https://app.pivotnow.in/stock/KILITCH) | ₹215.00 | ₹752 Cr | 24.2 | — |

## Questions and answers

### What is the share price of Themis Medicare today?

Themis Medicare (NSE: THEMISMED) last closed at ₹98.08 on 22 Oct 2026. Its 52-week high is ₹140.60 and its 52-week low is ₹64.95.

### What is the market cap of Themis Medicare?

Themis Medicare's market capitalisation is ₹903 Cr (₹903 Cr) at the 22 Oct 2026 close, ranking 1509th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Themis Medicare?

Return on equity was 7.5% in FY25 and return on capital employed was 12.5% in FY25 (standalone figures).

### Is Themis Medicare a debt-free company?

No. Themis Medicare's debt-to-equity ratio was 0.26 in FY25, with total debt of ₹22 Cr.

### What were Themis Medicare's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Themis Medicare reported revenue of ₹77 Cr, +6.7% year on year, and net profit of ₹2 Cr.

### How has Themis Medicare stock performed over the last year?

Themis Medicare's share price has fallen 22.8% over the past year, −9.1% over three months and −20.4% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Themis Medicare?

As of 30 Jun 2026: promoters 67.11%, foreign institutions 0.01%, domestic institutions 0.01%, non-institutions 32.87%. 43.39% of promoter shares were pledged.

### Who are Themis Medicare's competitors?

The listed Pharma & Healthcare companies closest to Themis Medicare by market cap are Lincoln Pharmaceuticals, Sigachi Industries, Laxmi Dental, Shree Ganesh Re, Anuh Pharma and Kilitch Drugs (India).

### Is Themis Medicare a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Themis Medicare's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on THEMISMED against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.